Press release
Lawsuit filed for Investors in shares of Fortress Biotech, Inc. (NASDAQ: FBIO)

A lawsuit was filed on behalf of investors in Fortress Biotech, Inc. (NASDAQ: FBIO) shares over alleged securities laws violations
Investors who purchased shares of Fortress Biotech, Inc. (NASDAQ: FBIO) have certain options and for certain investors are short and strict deadlines running. Deadline: January 26, 2021. NASDAQ: FBIO investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
In December 2019, the Company's majority-controlled subsidiary, Avenue Therapeutics, Inc. ("Avenue"), which Fortress Biotech, Inc. founded in 2015, submitted a New Drug Application ("NDA") for its intravenous ("IV") Tramadol product to the U.S. Food and Drug Administration ("FDA") for the management of moderate to moderately severe pain in adults in a medically supervised health care setting.
On October 12, 2020, Avenue Therapeutics, Inc disclosed receipt of a Complete Response Letter ("CRL") from the FDA regarding the NDA for its IV Tramadol product. Specifically, the FDA advised Avenue Therapeutics, Inc that "it cannot approve the application in its present form" because "IV tramadol, intended to treat patients in acute pain who require an opioid, is not safe for the intended patient population." Specifically, the CRL stated: "[I]f a patient requires an analgesic between the first dose of IV tramadol and the onset of analgesia, a rescue analgesic would be needed. The likely choice would be another opioid, which would result in opioid 'stacking' and increase the likelihood of opioid-related adverse effects."
Shares of Fortress Biotech, Inc. (NASDAQ: FBIO) declined from $4.78 per share in September 2020 to as low as $2.12 per share in November 2020.
The plaintiff claims that between December 11, 2019 and October 9, 2020, the Defendants made false and/or misleading statements and/or failed to disclose that IV Tramadol was not safe for the intended patient population, that as a result, it was foreseeable that the FDA would not approve the NDA for IV Tramadol, and that as a result, the Company's public statements were materially false and misleading at all relevant times.
Those who purchased shares of Fortress Biotech, Inc. (NASDAQ: FBIO) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lawsuit filed for Investors in shares of Fortress Biotech, Inc. (NASDAQ: FBIO) here
News-ID: 2204117 • Views: …
More Releases from Shareholders Foundation

Investigation announced for Investors in InMode Ltd. (NASDAQ: INMD) over possibl …
An investigation was announced over potential breaches of fiduciary duties by certain directors and officers of InMode Ltd.
Investors who are current long term investors in InMode Ltd. (NASDAQ: INMD) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: INMD stocks follows a lawsuit filed against InMode Ltd. over…

Lawsuit Alert: Investors who lost money with shares of Revance Therapeutics, Inc …
An investor, who purchased shares of Revance Therapeutics, Inc. (NASDAQ: RVNC), filed a lawsuit over alleged violations of Federal Securities Laws by Revance Therapeutics, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) between February 29, 2024 and December 6, 2024, and / or those who purchased anyNASDAQ: RVNC shares prior to February 2024 and continue…

Lawsuit filed for Investors who lost money with shares of AstraZeneca PLC (NASDA …
An investor, who purchased shares of AstraZeneca PLC (NASDAQ: AZN), filed a lawsuit in the U.S. over alleged violations of Federal Securities Laws by AstraZeneca PLC in connection with certain allegedly false and misleading statements made between February 23, 2022 and December 17, 2024.
Investors who purchased a significant amount of shares of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, have certain options and for certain…

Lawsuit filed for Investors who lost money with shares of Applied Therapeutics, …
An investor, who purchased shares of Applied Therapeutics, Inc. (NASDAQ: APLT), filed a lawsuit over alleged violations of Federal Securities Laws by Applied Therapeutics, Inc.
Investors who purchased shares of Applied Therapeutics, Inc. (NASDAQ: APLT) have certain options and for certain investors are short and strict deadlines running. Deadline: February 18, 2025. NASDAQ: APLT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
New York based Applied…
More Releases for Fortress
Doc Fortress Review: Read This Before Buying The DocFortress Fireproof Safe.
WHAT IF YOU LOST YOUR MOST VALUABLE POSSESSIONS?
WHAT WOULD YOU DO?
A fire has the potential to flip your life completely upside down. It has the ability to take everything from you. Everything, including your home, way of life, and most valued things. The feeling of helplessness that follows can be debilitating.
What would you do in this situation? What would you do if you could travel anywhere?
Sure, some things can be…
JRPG with a Twist: 'LV99: Final Fortress' out on 8 July
One and a half year after the release of 'Game Master Plus', an expanded and streamlined remake of the free japanese-style role-playing game 'Game Master', another Great Potion Games project has now been finished. The newest work of the Germany-based game developer and publisher is entitled 'LV99: Final Fortress' and will be available on Steam on 8 July 2020.
In 'LV99: Final Fortress', the player takes control of a heroine called…
Zenus Bank implements Fortress Identity Compound Biometrics
With the latest in technology and an international banking license, Zenus offers remote account opening for Deposits, Payments and Custody for individuals and companies worldwide for a truly borderless banking experience.
Zenus aims to give those living in emerging economies an alternative to using local banks by offering a new, transparent, digital banking experience on par with leading banks of the world.
Zenus claims that, “Within 15 minutes, a potential client can…
Biometric Authentication & Identification Global Market 2018: Key Players Crossm …
Introduction
Global Biometric Authentication & Identification has emerged as one of the fastest growing market around the globe. As the population and organizations are becoming more concerned towards the cyber security and safety, biometric authentication and identification provides a secure terminal which helps to keep place and data safe from unauthorized access. In fast couple of years, the physical security breaches have increased and due to this the global market…
Pipeline Detector Market Size 2017-2022 DETECTRONIC, Holiday Detectors, Fortress …
Global market study " Pipeline Detector Market Size 2017-2022 " analyses the crucial factors of the Pipeline Detector market based on present industry situations, market demands, business strategies adopted by Pipeline Detector market players and their growth scenario. This report isolates the Pipeline Detector market based on the key players, Type, Application and Regions.
The Pipeline Detector report provides the past, present and future Pipeline Detector industry Size, trends and…
CAEL-101 from Fortress Biotech (FBIO) Receives Orphan Drug Designations for Amyl …
U.S. Department of Health & Human Services has confirmed the transfer of two U.S. Food and Drug Administration (FDA) Orphan Drug Designations for CAEL-101 (also known as 11-1F4) from Columbia University (“Columbia”) to Fortress’ subsidiary, Caelum Biosciences, Inc. (“Caelum”). The two Orphan Drug Designations include the use of CAEL-101 as a therapeutic agent for patients with AL amyloidosis, and the use of CAEL-101 as a radio-imaging agent in amyloidosis.
Fortress…